Moderna and Merck announced a successful late-stage clinical trial of a personalized mRNA cancer vaccine that significantly reduces relapse rates in high-risk melanoma patients following tumor removal surgery [1, 2, 3, 4]. The drug, named intismeran autogene, uses mRNA technology similar to COVID-19 vaccines to train the immune system to target unique mutations in each patient’s tumor [1, 2, 3, 4].

The randomized trial included 1,137 patients who received either intismeran combined with pembrolizumab or pembrolizumab alone [1, 2, 3, 4]. The combination therapy notably improved relapse-free survival and distant metastasis-free survival compared with pembrolizumab alone, with no new safety concerns reported [3, 4].

Moderna CEO Stephane Bancel called the results "a remarkable milestone" for the company, mRNA science, and cancer patients [1]. Experts described the findings as a breakthrough for personalized cancer vaccines and a major advance in cancer immunotherapy [1, 2, 4]. London Barts Cancer Institute's Marco Gerlinger said, "This is not only good news for melanoma patients but a major breakthrough for the new generation of cancer immunotherapies" [4].

Following the announcement on August 19, 2026, Moderna's stock surged between 145% and 177% intraday, reaching roughly $154 to $174 per share—the largest single-day gain in company history [1, 2, 5, 6, 7, 8, 3, 9, 4]. Merck's shares also rose by about 12% to 13% to close near $152 per share [1, 2, 5, 7, 8, 3, 9, 4].

The companies plan to present full trial data at upcoming international medical conferences and begin regulatory filings for approval [1, 2, 3, 4]. The collaboration is also advancing research into using this mRNA technology for other cancers, including lung, bladder, and kidney tumors, with additional Phase 2 and 3 trials underway [1, 2, 3].

On August 19, the US Treasury revealed a plan to expand long-term government bond buybacks, causing a drop in bond yields and a partial rebound in US stocks after three days of declines [10, 11, 5, 6, 7, 12, 8, 3, 9, 4]. The Dow Jones rose approximately 119 to 165 points to about 53,463, the S&P 500 gained 16 to 40 points to roughly 7,708, and the Nasdaq climbed 41 to 135 points to near 26,331 [10, 11, 5, 6, 7, 12, 8, 3, 9].

The Moderna-Merck data release and share gains marked a sharp positive move in the market on a day otherwise marked by concerns about inflation, interest rates, geopolitical tensions, and Federal Reserve policy risks [11, 5, 6, 7, 12, 9].